SAR 440340

Drug Profile

SAR 440340

Alternative Names: REGN-3500; SAR-440340

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor-like 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Allergic asthma; Inflammation

Most Recent Events

  • 03 Oct 2017 Regeneron completes a phase I trial in Inflammation (In volunteers) in Belgium (IV) (SC) (NCT02958436)
  • 20 Apr 2017 Regeneron Pharmaceuticals and Sanofi plans a phase I trial for Allergic Asthma (Monotherapy, Combination therapy) (NCT03112577)
  • 01 Apr 2017 Phase-I clinical trials in Allergic asthma (Combination therapy) (unspecified route) (NCT03112577)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top